During the 7th China International Import Expo (CIIE), global biopharmaceutical company Takeda Pharmaceutical returned to the CIIE with a 600 square meter booth and made its global debut as the first rare disease gene therapy of its kind.
It is reported that BBM-H901 injection will make a major appearance at the Takeda Pharmaceutical booth and present its global debut. In the industry's view, as the first recombinant adeno-associated virus (AAV) gene therapy drug in China to successfully submit a new drug application for market launch, BBM-H901 is expected to lead the diagnosis and treatment of hemophilia in China into the era of gene therapy, rewriting the history of lifelong medication for hemophilia B patients.
In October 2023, Takeda China reached an exclusive cooperation agreement with Faith Medicine Group, and obtained the commercial operation license for BBM-H901 injection, a product under development by Faith Medicine, in mainland China, Hong Kong, and Macau. Takeda China stated that the debut of BBM-H901 injection is also a comprehensive effect of the new quality and productivity achievements of Faith Medicine loaded onto Takeda's leading commercial platform in the field of rare diseases in China, which will greatly accelerate the commercialization process of potential rare disease gene therapy in China.
According to public information, Takeda Pharmaceutical entered China in 1994 and officially established its production factory in Tianjin that same year. Over the past 30 years of deep cultivation in the Chinese market, Takeda Pharmaceuticals has continuously increased its investment in the Chinese market, building a complete pharmaceutical value chain layout from new drug development, production, drug supply and commercial operation.
Benefiting from the spillover effects of the CIIE, Takeda Pharmaceutical has successfully approved and launched over 15 innovative products in China from 2020 to 2024, covering the fields of oncology, digestion, and rare diseases. It has become one of the multinational pharmaceutical companies with the most newly approved products in recent years. In less than a year since the end of the previous CIIE, Takeda has been approved for six consecutive innovative products/indications in China. These innovative products are all "Jinbo Babies" that have been featured on previous CIIE platforms. Driven by the "accelerator" effect of the CIIE, they have been successfully launched and serve Chinese patients, becoming representative cases of "exhibits turning into commodities".
Dan Guohong, Senior Vice President of Takeda Pharmaceuticals and President of Takeda China, stated that the CIIE carries the grand vision of sharing opportunities between China and the world. As a beneficiary of the 'spillover effect' of the CIIE, Takeda continues to upgrade its development strategy in the Chinese market, by exploring the innovative potential of local new quality productivity, including gene therapy, and continuously strengthening the Chinese market, empowering China's medical innovation achievements with an international innovation model. Standing at a new starting point of 30 years of development in China, looking forward to the future, Takeda China will continue to uphold the original intention of 'putting patients first', leverage its unique advantages in commercial operation platforms, digitization, patient empowerment and other fields, deepen collaborative innovation with local partners, and help the Chinese medical and health ecosystem. Prosperous development, promoting Chinese pharmaceutical innovation towards a broader global market